What matters just as much — if not more — is everything around that number: how customers adopt the product, how sales actually happen, and whether the company is building something that can scale inside a complex, regulated system.
Sidewinder Therapeutics and Stipple Bio each raised mega-rounds of financing to support their approaches to improving the targeting abilities of antibody drug conjugates for cancer. Both startups are on track to enter the clinic next year.
Small practices play a critical role in healthcare delivery, but they cannot continue to absorb ever-increasing administrative demands without consequences.
Gilead Sciences is acquiring Ouro Medicines, a startup developing T cell engagers for a range of autoimmune diseases. Separately, Gilead is negotiating a deal with Galapagos to share in the development and potential commercialization of the Ouro drug.
Novartis already markets the PI3Kα inhibitor Piqray for breast cancer, but acquiring a Synnovation Therapeutics subsidiary brings an early clinical program that the pharma company claims could be best in the class of next-generation therapies for the target. Competitors include Eli Lilly, Relay Therapeutics, and OnKure Therapeutics.
Vima Therapeutics is expanding to Parkinson’s disease following early clinical results showed proof of concept for its drug in isolated dystonia, a rare neurological movement disorder. The startup says its drug could address the biology underpinning many movement disorders.
Valuing early-stage life sciences companies can be complex. Because product development can take several years and be capital intensive, obtaining an accurate valuation is essential to align management’s, the shareholders’, and current and potential investors’ understanding of estimated value.
Zelis highlights how employers, payers, and consumers are integrating digital tools to manage healthcare costs.
Novartis’s alliance with Unnatural Products is pursuing next-generation peptide drugs for cardiovascular disease. The startup already has drug R&D alliances with BridgeBio Pharma, Merck, and Argenx.
Matthias Kleinz, executive vice president and head of translational sciences investments at UPMC Enterprises, explained why biopharma companies cannot ignore China anymore.
In today's dynamic environment, companies are navigating deal-making and innovation spurred by the vertical integration of AI and a rebounding IPO market. Here are ten global trends poised to define the industry in the coming year.
Arthrosi Therapeutics’ pozdeutinurad is in Phase 3 testing as a treatment for uncontrolled gout. Sobi says this once-daily capsule complements its own asset, an infused biologic medicine currently under FDA review as a third-line gout treatment.
How to turn analytics into actual policy outcomes.
Chiesi Global Rare Diseases is committing up to $115 million to begin a collaboration on Arbor Biotechnologies’ in vivo gene-editing therapy for primary hyperoxaluria type 1, an inherited liver disorder. It’s the rare disease company’s first foray into genetic medicines.
Dualitas Therapeutics designs bispecific antibodies to hit to two targets on the same immune cell, leveraging proximity biology to provide benefit beyond what’s possible with monoclonal antibody drugs. Eli Lilly and Chugai Pharmaceutical are among the investors in the immunology and inflammation startup.
AllRock Bio’s drug is a small molecule pan-ROCK inhibitor ready for Phase 2 testing in pulmonary arterial hypertension and pulmonary hypertension with interstitial lung disease. The startup is led by the management team that steered CinCor Pharma to a $1.3 billion acquisition by AstraZeneca.
The keys are establishing a culture that applauds ideas and learns from “failures” rather than seeking to place blame, recognizing that the best ideas can come from any source, and benefiting from cross-functional discussion and challenge.
The Phase 3 results in China are encouraging for Kailera Therapeutics, which holds rights to the molecule in the rest of the world. The startup is preparing a global clinical development program for this drug, a once-weekly injectable GLP-1 and GIP receptor agonist.